Related references
Note: Only part of the references are listed.Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients
Anne Froehlich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma Pooled Analysis of 3 Clinical Trials
Igor Puzanov et al.
JAMA ONCOLOGY (2020)
LONG-TERM ANALYSIS OF MASTERKEY-265 PHASE 1B TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) PLUS PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE STAGE IIIB-IVM1C MELANOMA
Georgina Long et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab
Muhammad Z. Afzal et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety
Steven S. Raman et al.
IMMUNOTHERAPY (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
Lillian Sun et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A practical guide to the handling and administration of talimogene laherparepvec in Europe
Kevin J. Harrington et al.
ONCOTARGETS AND THERAPY (2017)
Local Delivery of OncoVEXmGM-CSF Generates Systemic AntitumorImmuneResponses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade
Achim K. Moesta et al.
CLINICAL CANCER RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
Casey Quinn et al.
ADVANCES IN THERAPY (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
James E. Signorovitch et al.
VALUE IN HEALTH (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
No Head-to-Head Trial? Simulate the Missing Arms
J. Jaime Caro et al.
PHARMACOECONOMICS (2010)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)